AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Key Points

Abstract

Cite This Study